Thanks Steed.
It appears from my understanding that there may be away to get Daybue to other countries on a patient by patient scenario before regulatory approval is granted, and maybe insurance companies may also assess each case individually as per the first post about this topic. It seems Daybue meets those criteria set out above.
Another post mentioned that "RSE organisation is doing work...to get it in Europe."
But I have no idea what RSE stands for.
So maybe we might have some limited access to ROW earlier, however one would think there needs to be approval from individual insurances to cover the high cost (as the first person suggested with their letter)
I'd be interested to know what others thought or whether they'd heard of this happening for other medications in the past.
Daybue Feedback, page-19
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.40 |
Change
1.130(8.52%) |
Mkt cap ! $1.840B | |||
| Open | High | Low | Value | Volume |
| $13.80 | $14.45 | $13.53 | $15.04M | 1.062M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 871 | $14.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.42 | 3650 | 3 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |